This loss of expression has been associated with tumor progression and drug resistance, particularly in response to therapies targeting chromatin histone acetylation and Meiotic Recombination 11 (MRE11) (https://cancer.sanger.ac.uk). The gene discussed is MRE11; the disease is neoplasm.